Follow Ups | Post Followup | Back to Discussion Board | VegSource
See spam or
inappropriate posts?
Please let us know.

From: TSS (
Subject: STERIS Announces Research Breakthrough in Inactivating Deadly Prions
Date: August 6, 2004 at 12:55 pm PST

STERIS Announces Research Breakthrough in Inactivating Deadly Prions

Mentor, Ohio (August 6, 2004) - STERIS Corporation (NYSE:STE) today
announced that the Company, in cooperation with leading independent
prion researchers, has participated in research that indicates the
effectiveness of several of the Company's proprietary cleaning and
sterilization technologies in inactivating prions. Prions are proteins
that have been associated with debilitating and fatal illnesses in both
animals and humans. Until now, it has not been possible to inactivate
prions without damaging contaminated surfaces. STERIS has introduced a
new consumable product in its Healthcare segment, and is re-introducing
an established consumable product in its Life Sciences segment to
address prion concerns in both of its major industries.

This research has been published in the August 7, 2004 edition of The
Lancet, an international journal of medical science and practice. Prions
are extremely difficult to inactivate from the surfaces of surgical
instruments or other items that may be contaminated and are believed to
be the causative agent of Transmissible Spongiform Encephalopathy (TSE),
a group of fatal animal and human diseases that affect the central
nervous system. Examples of such diseases in animals include scrapie and
bovine spongiform encephalopathies (BSE), which is commonly known as Mad
Cow Disease. Human variations include Creutzfeldt Jacob Disease (CJD)
and variant Creutzfeldt Jacob Disease (vCJD).

Commenting on the research, Les C. Vinney, STERIS's President and Chief
Executive Officer, said, "We are pleased to have been involved in such
critically important research and to have our collaborative research
recognized by The Lancet. This research further confirms the value of
our technology portfolio and our belief that we can leverage our
capabilities to advance the science of sterilization and
decontamination. STERIS continues to provide cutting edge innovations to
combat the latest and toughest infection and decontamination challenges.

We believe there are other opportunities available to STERIS to
commercialize additional new products to address the impact of TSE's and
we are continuing to pursue these opportunities."

As a result of this research, the Company's Healthcare segment has
introduced a new product in the United Kingdom (U.K.). The product is a
cleansing solution designed to be added to the washing-disinfecting
cycle of washers that decontaminate surgical instruments after use, and
will be sold under the brand name Hamo 100 PID (Prion Inactivation
Detergent). In addition, the Life Sciences segment is re-introducing a
cleaning solution currently on the market that, as part of this
research, has been proven to be effective against prions. The product,
CIP 100, is a leading solution used to clean pharmaceutical and
biotechnology production equipment. The Company is in the process of
exploring additional commercialization opportunities for this and other
tested technologies.

In the process of its work with prions, STERIS also helped develop
standardized testing and validation protocols that were used to confirm
the validity of the test results. These validation protocols are being
made available to test the effectiveness of various other
decontamination methods against prions to advance research in these
specialized areas.


The mission of STERIS Corporation is to provide a healthier today and
safer tomorrow through knowledgeable people and innovative infection
prevention, decontamination, and health science technologies, products,
and services. Additional information about STERIS can be found on the
Company's Website at .

Contact: Aidan Gormley, Senior Director, Corporate Communications and
Investor Relations at 440-392-7607.

This news release may contain statements concerning certain trends,
expectations, forecasts, estimates, or other forward-looking information
affecting or relating to the Company or its industry that are intended
to qualify for the protections afforded "forward-looking statements"
under the Private Securities Litigation Reform Act of 1995 and other
laws and regulations. Forward-looking statements speak only as to the
date of this report, and may be identified by the use of forward-looking
terms such as "may," "will," "expects," "believes," "anticipates,"
"plans," "estimates," "projects," "targets," "forecasts," and "seeks,"
or the negative of such terms or other variations on such terms or
comparable terminology. Many important factors could cause actual
results to differ materially from those in the forward-looking
statements including, without limitation, disruption of production or
supplies, changes in market conditions, political events, pending or
future claims or litigation, competitive factors, technology advances,
and changes in government regulations or the application or
interpretation thereof. Other risk factors are described in the
Company's Form 10-K and other securities filings. Many of these
important factors are outside STERIS's control. No assurances can be
provided as to any future financial results. Unless legally required,
the Company does not undertake to update or revise any forward-looking
statements even if events make clear that any projected results, express
or implied, will not be realized. Other potential risks and
uncertainties that could cause actual results to differ materially from
those in the forward-looking statements include, without limitation, (a)
the potential for increased pressure on pricing that leads to erosion of
profit margins, (b) the possibility that market demand will not develop
for new technologies, products or applications, or the Company's
business initiatives will take longer, cost more or produce lower
benefits than anticipated, ( c) the possibility that compliance with
laws, court rulings, regulations, or certification requirements of
domestic and foreign authorities may delay or prevent new product
introductions, affect the production and marketing of existing products,
or otherwise affect Company performance, (d) the potential of
international unrest or effects of fluctuations in foreign currencies of
countries where the Company does a sizeable amount of business, and (e)
the possibility of reduced demand, or reductions in the rate of growth
in demand, for the Company's products and services.


Follow Ups:

Post a Followup

E-mail: (optional)


Optional Link URL:
Link Title:
Optional Image URL: